COVALENT GROUP GETS $3.4 MILLION IN NEW BUSINESS AWARDS.
Kenneth M. Borow, M.D., president and CEO, commented, "We are proud to add three new companies to the Covalent family of clients. These contract awards position Covalent for future additional business with these as well as other clients in the United States and Europe. The inclusion of work in four different therapeutic areas is consistent with Covalent's mission of leadership in the design and conduct of clinical trials across a wide array of disease states. We are particularly encouraged by the geographic distribution of these contract awards and believe that our strategy of pursuing business development opportunities on a multi-national, multi-continent basis is beginning to produce results."
Covalent Group, Inc. is a clinical research organization that is a leader in the design and management of complex clinical trials for the pharmaceutical, biotechnology and medical device industries. The company's mission is to provide its clients with high quality, full-service support for their clinical trials. Covalent offers therapeutic expertise, experienced team management and advanced technologies. The company has clinical trial experience across a wide variety of therapeutic areas such as cardiovascular, endocrinology/metabolism, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Covalent believes that its leadership in the design of complex clinical trials, its application of innovative technologies, therapeutic expertise and commitment to quality offer its clients a means to more quickly and cost effectively develop products through the clinical trial process. In addition, the company's use of its proprietary TeleTrial(R) technology to support its drug development services creates consistency in the way it conducts clinical trials globally. With its wholly owned international subsidiary, Covalent Group, Ltd., Covalent is able to meet many of the global drug development needs of its clients.
For more information, call 610/975-9533 or visit http://www.covalentgroup.com.
|Printer friendly Cite/link Email Feedback|
|Publication:||Biotech Financial Reports|
|Date:||Aug 1, 2003|
|Previous Article:||NORAC SIGNS LETTER OF INTENT FOR AMALGAMATION WITH VIREXX.|
|Next Article:||ORPHAN MEDICAL REPORTS OVER 20% INCREASE IN 2ND QTR REVENUES.|